Welcome to Bristol Myers Squibb California
Bristol Myers Squibb’s robust and growing presence in California is transforming the way cancer and other difficult-to-treat diseases are approached.
Scientists and researchers with diverse backgrounds and expertise in Brisbane, Redwood City, San Diego and San Francisco collaborate across teams, functions and sites to follow their own scientific curiosity, enabling fast, flexible science that ultimately increases the efficiency and success of drugs in the clinic. These efforts, at a time when the pace of technological advancements and creation of new biomedical knowledge is accelerating, are laying the foundation for investigational molecules that may one day have a significant therapeutic impact.
Meet our team
Learn about our leaders who are making a difference in California.
Neil Bence, PhD, leads a team that is responsible for cancer biology research, identifying new targets and supporting the company’s hematology and solid tumor oncology drug discovery pipeline.
Michael Pourdehnad, MD, leads early clinical development programs across both internal and partnered assets for a diverse range of treatment modalities, with a focus on targeted protein degradation.
Amy Sehnert, MD, leads a team working to develop precision therapeutics for serious cardiovascular disorders, with a specific focus on diseases of heart muscle and heart failure.
Ralston Barnes is the scientific director of Transgenic Discovery group in Discovery Biotherapeutics in Redwood City, California.
Miranda Broz, PhD, serves as a scientific associate director of Discovery Myeloid Biology at Bristol Myers Squibb’s R&D site in Redwood City, California
Ching-Pin (CP) Chang, MD, PhD, leads a team that discovers and develops targeted therapies for serious cardiovascular diseases by studying the biology of hypertrophic cardiomyopathy and other cardiovascular conditions.
Kristen Hege, MD, is responsible for overseeing early clinical development programs for a diverse range of treatment modalities such as CAR T cells, T-cell engagers, monoclonal antibodies and small molecules.
Ashley Koegel, MD, leads the design and implementation of clinical studies to assess the safety and efficacy of potential medicines in the company’s pipeline.
Debbie Law (DPhil) is head of Bristol Myers Squibb’s Tumor Microenvironment (TME) Thematic Research Center, leading a team of researchers who explore the complexities of tumors, with a specific focus on the environment the tumor creates.
Johan Oslob, PhD, leads a team of researchers that discovers small molecules that modulate disease-causing pathways through novel interactions and uses these small-molecule modulators for preclinical validation as well as starting points for chemical optimization to obtain refined molecules with properties that may be suitable for a medicine.
Chétna Rao, PhD, serves as the head of global R&ED STEM strategy for Bristol Myers Squibb, where she oversees STEM initiatives across the R&ED landscape.
Mark Rolfe, PhD, leads an early drug discovery team focused on targeted protein degradation – removing disease-causing proteins from cells by leveraging the body’s natural system of maintaining balanced protein levels.
Principal Scientist, Protein Homeostasis Structural Biology, San Diego, CA
Join us as we transform patient lives through science
Every day, each of us work to improve outcomes of patients fighting serious diseases. Together we’re building a better future for each other and the patients who need us the most.
Driving innovation forward in California
Learn about our broad scope of scientific innovation in California.
Hear from our team in San Diego about the collaborative, passionate culture that inspires their work in protein homeostasis, discovery biotherapeutics and global drug development in other therapeutic areas as they discover and develop innovative new therapies for difficult-to-treat diseases that transform patients’ lives.
As a scientific research community, our work is never done for cancer patients. Building upon established science allows researchers to pursue new approaches, test new hypotheses and – ultimately – uncover new answers to emerging and enduring questions that may address unmet needs for patients.
Blood disease and cancer specialist Kristen Hege, who has been board-certified in hematology, medical oncology and internal medicine, joined BMS through the 2019 Celgene acquisition as the senior vice president of Early Clinical Development, Hematology/Oncology & Cell Therapy. She brings decades of CAR T cell therapy expertise to the company.
Community impact
Learn about how we are making a difference in communities across California
Learn about how Bristol Myers Squibb’s internship program in the Bay Area is inspiring a new generation of physicians and scientists from communities who have been historically underrepresented in STEM.
Additional resources
Learn more about our scientific approaches and innovation.